Cargando…
Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
BACKGROUND: With increasing numbers of oncology biosimilars in the approval pipeline, it is important to investigate oncology clinicians’ understanding of biosimilars and what information they need prior to adoption. METHODS: Between January and May 2018, 77 oncology clinicians (52 physicians, 16 ph...
Autores principales: | Cook, John W., McGrath, Megan K., Dixon, Margie D., Switchenko, Jeffrey M., Harvey, R. Donald, Pentz, Rebecca D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327341/ https://www.ncbi.nlm.nih.gov/pubmed/30671144 http://dx.doi.org/10.1177/1758835918818335 |
Ejemplares similares
-
Dissemination of validated health literacy videos: A tailored approach
por: Blee, Shannon M., et al.
Publicado: (2022) -
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018) -
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
por: Tabernero, Josep, et al.
Publicado: (2017) -
Biosimilar Insulins – What a Clinician Needs to Know?
por: Ghosh, Sujoy, et al.
Publicado: (2019) -
Biosimilars: potential implications for clinicians
por: Eleryan, Misty G, et al.
Publicado: (2016)